PDL BioPharma Inc. (NDAQ:PDLI) shares are down five percent today after Daniel Loeb's Third Point disclosed that they sold the rest of their stake in the company. Last month, the activist hedge fund announced that it cut its stake from 9.7 to 5.1 percent but noted that it was encouraged by the board's plan to sell the company - an effort that it spearheaded.

Many shareholders have sold out of PDLI as it made the WSJ's largest outflow of capital. The selling on strength suggests that some investors may be concerned that a potential deal may have trouble in today's markets. Several deals have fallen through after most banks have included clauses in their financing packages that let them get out of deal early if markets get worse.

PDLI minus their number one activist shareholder may now be tempted to abandon its sale process. This is especially true after the company announced narrowed losses in the third quarter. The company continues to lose money as a result of restructuring charges, but did manage to improve bottom line results. There have also been several layoffs and other efforts to reduce costs.

In the end, the situation may go downhill from here. Shares have rallied substantially since the hedge fund got involved and there may now be a sideways trading period after they exited amid a run-up. Whether or not the company will be sold remains to be seen, but this is still a stock that is definitely worth watching over the next few months!

Related Companies
Genentech Inc. (DNA)
Medarex Inc. (MEDX)
Immunomedics Inc. (IMMU)